Nyxoah’s Genio Wins Prix Galien UK 2026 for Best Medical Technology

Event summary

  • Nyxoah’s Genio® hypoglossal nerve stimulation therapy won the Prix Galien UK 2026 Award for Best Medical Technology on June 15, 2026.
  • The award recognizes Genio’s contribution to treating Obstructive Sleep Apnea (OSA), a condition affecting millions.
  • Nyxoah recently secured new financing to accelerate U.S. expansion following FDA approval in August 2025.
  • The company has expanded its therapeutic indications to include Complete Concentric Collapse (CCC) patients, a segment contraindicated in competitors’ therapies.

The big picture

Nyxoah’s Prix Galien win underscores the growing recognition of its Genio system as a breakthrough in OSA treatment. The award comes at a pivotal moment as the company accelerates U.S. expansion following FDA approval and secures financing to support its growth. The strategic focus on expanding therapeutic indications and international adoption positions Nyxoah to capture a larger share of the sleep disorder treatment market.

What we're watching

U.S. Market Penetration
How Nyxoah will leverage its FDA approval and new financing to scale Genio’s adoption in the U.S.
Competitive Differentiation
Whether Nyxoah’s expansion into CCC patients will sustain its competitive edge over rivals.
Global Expansion
The pace at which Nyxoah can grow its presence in Europe and other international markets.

Related topics

FDA Approval